Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
industry-outlook: Archive
DLocal (DLO) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
DLocal (DLO) delivered earnings and revenue surprises of -36.36% and 5.54%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
DLOPositive Net Change GBNo Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Prestige Consumer Healthcare (PBH) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of -10.53% and 3.46%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
PBHPositive Net Change QIPTPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Globe Specialty Metals (GSM) Reports Break-Even Earnings for Q1
by Zacks Equity Research
Globe Specialty Metals (GSM) delivered earnings and revenue surprises of 100% and 14.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GSMPositive Net Change UECPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
The Oncology Institute, Inc. (TOI) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
The Oncology Institute (TOI) delivered earnings and revenue surprises of -83.33% and 0.53%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
TOINegative Net Change ICCMNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Seadrill (SDRL) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Seadrill (SDRL) delivered earnings and revenue surprises of 19.12% and 0.14%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
SDRLNegative Net Change REXPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TFF Pharmaceuticals (TFFP) delivered earnings and revenue surprises of -9.09% and 35.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
TFFPPositive Net Change LUMONegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Iridex (IRIX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Iridex (IRIX) delivered earnings and revenue surprises of -75% and 1.99%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
IRIXNegative Net Change ITIPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Asensus Surgical (ASXC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Asensus Surgical (ASXC) delivered earnings and revenue surprises of -40% and 2.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ASXCNegative Net Change AVGRNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Nu Holdings Ltd. (NU) Q1 Earnings Match Estimates
by Zacks Equity Research
Nu (NU) delivered earnings and revenue surprises of 0% and 5.92%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
NUPositive Net Change RAMPNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Genasys (GNSS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Genasys (GNSS) delivered earnings and revenue surprises of -33.33% and 18.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GNSSPositive Net Change BJPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Nextracker (NXT) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Nextracker (NXT) delivered earnings and revenue surprises of 62.71% and 8.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
NXTPositive Net Change MAXNNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Pixelworks (PXLW) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pixelworks (PXLW) delivered earnings and revenue surprises of 12.50% and 0.34%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
PXLWPositive Net Change AVGOPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
scPharmaceuticals (SCPH) delivered earnings and revenue surprises of 20% and 6.17%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
SCPHNegative Net Change ALVOPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Precigen (PGEN) delivered earnings and revenue surprises of -11.11% and 30.84%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
PGENPositive Net Change MYNZPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Bridgeline Digital, Inc. (BLIN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Bridgeline Digital (BLIN) delivered earnings and revenue surprises of 66.67% and 0.16%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
BLINPositive Net Change ZSNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of 9.09% and 7.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
TSHAPositive Net Change SLGLNo Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Eos Energy Enterprises, Inc. (EOSE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Eos Energy Enterprises (EOSE) delivered earnings and revenue surprises of 4.17% and 0.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
EOSEPositive Net Change PPSIPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Jack In The Box (JACK) Beats Q2 Earnings Estimates
by Zacks Equity Research
Jack In The Box (JACK) delivered earnings and revenue surprises of 2.10% and 1.18%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
JACKPositive Net Change RRGBPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
On Holding (ONON) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
On Holding (ONON) delivered earnings and revenue surprises of 137.50% and 4.66%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ONONPositive Net Change ASOPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of 26.09% and 40.95%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
OVIDNegative Net Change FBIOPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Kopin (KOPN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kopin (KOPN) delivered earnings and revenue surprises of 0% and 11.98%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
KOPNPositive Net Change EXROFPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Immunome (IMNM) delivered earnings and revenue surprises of 57.50% and 74.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
IMNMNegative Net Change AQBNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Pyxis Oncology, Inc. (PYXS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pyxis Oncology (PYXS) delivered earnings and revenue surprises of 77.78% and 279.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
PYXSNegative Net Change COSMPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -200% and 2.99%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ALIMNegative Net Change OVIDNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
CareCloud, Inc. (CCLD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
CareCloud (CCLD) delivered earnings and revenue surprises of 93.75% and 2.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
CCLDNegative Net Change NYXHPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank